Saqib Islam Buys Shares of ARS Pharmaceuticals

Saqib Islam, an insider at ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), purchased 30,000 shares of the company on June 24, 2026. This insider transaction did not occur under a pre-planned 10b5-1 trading plan. Shares traded around $8.54 on Saturday.

Insider Buying and Selling at ARS Pharmaceuticals, Inc.

Alongside Saqib Islam, several other insiders, including Peter Thompson, Laura Shawver, Rajeev Dadoo, and Brent Saunders, also bought 30,000 shares each on the same date. These transactions reflect a collective insider confidence in ARS Pharmaceuticals' prospects.

Other Institutional Activity in ARS Pharmaceuticals

In recent institutional activity, Rubric Capital Management LP increased its holdings by 1,800,000 shares, bringing its total to 8,000,000 shares valued at approximately $64.24 million, marking a 29% increase. Millennium Management LLC also added 2,814,513 shares, ending with 5,982,919 shares worth about $48.04 million, reflecting an 88.8% increase. Meanwhile, BlackRock, Inc. reduced its position slightly by 73,063 shares, holding 5,012,254 shares valued at $40.25 million, a 1.4% decrease.

ARS Pharmaceuticals, Inc. Stock Up 45.0%

Shares of ARS Pharmaceuticals traded near $8.54 on Saturday. The company, with a market cap of about $848 million, operates in the biotechnology industry. It has a forward P/E ratio of -10.32, indicating it is not currently profitable. The stock has experienced a 52-week low of $6.66 and a high of $18.90. Its 50-day moving average is $8.70, and the 200-day moving average is $9.36. The current ratio stands at 4.94, with a quick ratio of 4.65, and a debt-to-equity ratio of 279.24.

Analysts Set New Price Targets

On June 25, 2026, Leerink Partners maintained its buy rating for ARS Pharmaceuticals with a price target of $24. Cantor Fitzgerald also maintained its buy rating with a target of $30 on May 28, 2026. The consensus among analysts is a strong buy, with a target mean price of $28.40 based on five analyst opinions.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. is a biotech company based in San Diego, California. Founded in 2015, the company focuses on developing treatments for severe allergic reactions. Its flagship product, neffy, is an innovative needle-free intranasal delivery of epinephrine for emergency treatment of anaphylaxis. Led by CEO Richard E. Lowenthal, ARS Pharmaceuticals employs 154 people and aims to provide effective solutions for allergy sufferers.

Bottom Line

Insider transactions, such as Saqib Islam's recent purchase of ARS Pharmaceuticals shares, often draw investor attention as they may signal confidence in the company's future. While the 13F filings and insider trades offer a backward-looking view, this activity, combined with strong buy ratings from analysts, keeps ARS Pharmaceuticals in the spotlight for investors keeping an eye on the biotech sector.